Evaxion A/S: Financial statements 2014
CVR: 31762863
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
Evaxion A/S (CVR 31762863) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK -399,331 and a net result of DKK -1,518,749 compared with DKK 419,463 the year before. Equity in the 2014 report amounted to DKK 9,859,336. The solvency ratio was 93.5%.
- Gross Profit
- DKK -399,331
- Profit/Loss
- DKK -1,518,749
- Equity
- DKK 9,859,336
- Total Assets
- DKK 10,541,896
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | -399 t. | -1.5 mio. | 9.9 mio. | - |
| 2013 | - | 518 t. | 419 t. | 539 t. | - |
| 2012 | 1.4 mio. | - | 324 t. | 119 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of December 16, 2014, Lars Aage Staal Wegner has joined the board of directors of Evaxion A/S.
As of December 16, 2014, Thomas William Wylonis has joined the board of directors of Evaxion A/S.
As of December 15, 2014, Lars Aage Staal Wegner has left the board of directors of Evaxion A/S.
As of December 15, 2014, Thomas William Wylonis has left the board of directors of Evaxion A/S.
As of September 18, 2014, Roberto Prego Novo has joined the board of directors of Evaxion A/S.
Evaxion A/S has published its annual report for 2013. Gross profit came to DKK 518,400, and the net result was DKK 419,463.
As of March 21, 2014, Lars Aage Staal Wegner has joined the board of directors of Evaxion A/S.
As of March 21, 2014, Thomas William Wylonis has joined the board of directors of Evaxion A/S.
On March 21, 2014, the company changed its name from NOVVAC ApS to EVAXION BIOTECH ApS.
About Evaxion A/S
Evaxion A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2008. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named EVAXION BIOTECH A/S and EVAXION BIOTECH ApS. The management consists of Helen Katrina Tayton-Martin, Andreas Holm Mattsson and Thomas Frederik Schmidt. The board consists of Marianne Søgaard (chair), Jens Bitsch-Nørhave, Lars Holtug and Lars Aage Staal Wegner. The company is owned by BNY (Nominees) Limited (as nominee of The Bank of New York Mellon). The company has 24 employees (2018). In 2025, the company reported revenue of DKK 48,112,000 and a net result of DKK -51,489,000 compared with DKK -73,277,000 the year before. Equity in the 2025 report amounted to DKK 108,250,000.